Rebecca A Baillie

List of Publications by Year
in descending order

56	4,927	186265 28	182427 51
papers	citations	h-index	g-index

66	66	66	7429
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Integrative metabolomicsâ€genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1260-1278.	0.8	57
2	APOE Îµ2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. Alzheimer's and Dementia, 2022, 18, 2151-2166.	0.8	16
3	Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression. Brain Communications, 2021, 3, fcab139.	3.3	21
4	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Translational Psychiatry, 2021, 11, 153.	4.8	46
5	Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature. Scientific Reports, 2021, 11, 21011.	3.3	37
6	Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimerâ€™s Disease. Cell Reports Medicine, 2020, 1, 100138.	6.5	102
7	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 5698.	12.8	76
8	Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. Alzheimer's and Dementia, 2020, 16, 1234-1247.	0.8	15
9	Peripheral serum metabolomic profiles inform central cognitive impairment. Scientific Reports, 2020, 10, 14059.	3.3	25
10	Serum triglycerides in Alzheimer disease. Neurology, 2020, 94, e2088-e2098.	1.1	63
11	Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level. PLoS ONE, 2020, 15, e0234683.	2.5	24
12	Sex and APOE Îµ4 genotype modify the Alzheimerâ€™s disease serum metabolome. Nature Communications, 2020, 11, 1148.	12.8	115
13	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Network Open, 2019, 2, e197978.	5.9	142
14	Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts. Scientific Data, 2019, 6, 212.	5.3	15
15	Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 619-627.	2.4	45
16	Considerations for Adapting Pre-existing Mechanistic Quantitative Systems Pharmacology Models for New Research Contexts. Frontiers in Pharmacology, 2019, 10, 416.	3.5	1
17	A blood-based signature of cerebrospinal fluid AÎ²1â€“42 status. Scientific Reports, 2019, 9, 4163.	3.3	21
18	Altered bile acid profile associates with cognitive impairment in Alzheimer's diseaseâ€”An emerging role for gut microbiome. Alzheimer's and Dementia, 2019, 15, 76-92.	0.8	396

#	Article	IF	Citations
19	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimer's and Dementia, 2019, 15, 232-244.	0.8	198
20	Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. Journal of the American Heart Association, 2018, 7, .	3.7	19
21	F3â€02â€04: SERUM INDICES OF ETHANOLAMINE PLASMALOGENS AND PHOSPHATIDE METABOLISM IN THE COMBINED ADNIâ€1/GO/2 COHORT: DOES THE LIVER CONTRIBUTE TO AD RISK BY FAILING TO SUPPLY KEY LIPIDS TO THE BRAIN?. Alzheimer's and Dementia, 2018, 14, P998.	0.8	1
22	F3â€02â€01: ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P997.	0.8	0
23	Generation and quality control of lipidomics data for the alzheimerâ€™s disease neuroimaging initiative cohort. Scientific Data, 2018, 5, 180263.	5.3	55
24	F3â€02â€03: ASSOCIATION OF SERUM LIPIDS WITH ALZHEIMER'S DISEASE IN THE ADNI COHORT: AN UNTARGETED LIPIDOMICS STUDY. Alzheimer's and Dementia, 2018, 14, P998.	0.8	0
25	Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 525-533.	2.5	14
26	Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Medicine, 2018, 15, e1002482.	8.4	336
27	Metabolic network failures in Alzheimer's disease: A biochemical roadÂmap. Alzheimer's and Dementia, 2017, 13, 965-984.	0.8	362
28	Pharmacometabolomic signature links simvastatin therapy and insulin resistance. Metabolomics, 2017, 13, 1.	3.0	14
29	Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Scientific Data, 2017, 4, 170140.	5.3	49
30	[F2â€“01â€“03]: GUT DERIVED BILE ACID METABOLITES CORRELATE WITH STRUCTURAL AND FUNCTIONAL NEUROIMAGING MEASURES IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P543.	0.8	0
31	P3-157: Indices of Plasmalogen Biosynthesis in ADNI-1 Baseline Serum Samples: Association with Progression to Dementia in Subjects with Mild Cognitive Impairment. , 2016, 12, P879-P880.		1
32	F1-02-02: Genetic Influence on Levels of Targeted Metabolites Associated with Alzheimerâ€™s Disease. , 2016, 12, P164-P165.		0
33	Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models. Frontiers in Pharmacology, 2014, 5, 232.	3.5	14
34	Pharmacokinetic analysis of ¹⁴Câ€ursodiol in newborn infants using accelerator mass spectrometry. Journal of Clinical Pharmacology, 2014, 54, 1031-1037.	2.0	18
35	Is a Diabetes Mellitusâ€“Linked Amino Acid Signature Associated With Î²-Blockerâ€“Induced Impaired Fasting Glucose?. Circulation: Cardiovascular Genetics, 2014, 7, 199-205.	5.1	21
36	Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics. PLoS ONE, 2013, 8, e68717.	2.5	104

#	Article	IF	Citations
37	Impaired plasmalogens in patients with schizophrenia. Psychiatry Research, 2012, 198, 347-352.	3.3	63
38	Metabolomics Reveals Amino Acids Contribute to Variation in Response to Simvastatin Treatment. PLoS ONE, 2012, 7, e38386.	2.5	90
39	Plasma Omega-3 Polyunsaturated Fatty Acids and Survival in Patients with Chronic Heart Failure and Major Depressive Disorder. Journal of Cardiovascular Translational Research, 2012, 5, 92-99.	2.4	27
40	Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment. PLoS ONE, 2011, 6, e25482.	2.5	172
41	Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics, 2010, 6, 191-201.	3.0	98
42	Functional Annotation of Genomic Data with Metabolic Inference. Poultry Science, 2007, 86, 1510-1522.	3.4	8
43	A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology, 2007, 46, 1081-1090.	7.3	1,096
44	Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular Psychiatry, 2007, 12, 934-945.	7.9	241
45	Targeted Deletion of FATP5 Reveals Multiple Functions in Liver Metabolism: Alterations in Hepatic Lipid Homeostasis. Gastroenterology, 2006, 130, 1245-1258.	1.3	200
46	Chapter 27. Biosimulation: Dynamic modeling of biological systems. Annual Reports in Medicinal Chemistry, 2002, 37, 279-288.	0.9	7
47	Copper Deficiency Induces Hepatic Fatty Acid Synthase Gene Transcription in Rats by Increasing the Nuclear Content of Mature Sterol Regulatory Element Binding Protein 1. Journal of Nutrition, 2000, 130, 2915-2921.	2.9	42
48	Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors. American Journal of Clinical Nutrition, 1999, 70, 566-571.	4.7	110
49	Coordinate induction of peroxisomal acyl-CoA oxidase and UCP-3 by dietary fish oil: a mechanism for decreased body fat deposition. Prostaglandins Leukotrienes and Essential Fatty Acids, 1999, 60, 351-356.	2.2	154
50	Regulation of the Action of Steroid/Thyroid Hormone Receptors by Medium-chain Fatty Acids. Journal of Biological Chemistry, 1998, 273, 15373-15381.	3.4	16
51	Hepatic fatty acid synthase gene transcription is induced by a dietary copper deficiency. American Journal of Physiology - Endocrinology and Metabolism, 1997, 272, E1124-E1129.	3.5	8
52	Fatty Acid Regulation of Gene Expression Its Role in Fuel Partitioning and Insulin Resistance. Annals of the New York Academy of Sciences, 1997, 827, 178-187.	3.8	56
53	Specific effects of polyunsaturated fatty acids on gene expression. Current Opinion in Lipidology, 1996, 7, 53-55.	2.7	12
54	Nutritional and Hormonal Regulation of Expression of the Gene for Malic Enzyme. Progress in Molecular Biology and Translational Science, 1996, 52, 89-122.	1.9	45

#	Article	IF	Citations
55	Transient transfection of chick-embryo hepatocytes. Journal of Nutritional Biochemistry, 1993, 4, 431-439.	4.2	24
56	Characterization of an Acrosomal Matrix Protein in Hamster and Bovine Spermatids and Spermatozoa1. Biology of Reproduction, 1990, 42, 553-562.	2.7	11